Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos
January 12, 2011
Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos
Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Brain Imaging, Cognitive Evaluation Link TOMM40 Alterations to Alzheimer's Risk in Healthy Patients
July 14, 2010 / Pharmacogenomics Reporter - Researchers Publish Data on Gene Variant Associated with Late-Onset Alzheimer's Disease
January 6, 2010 / Pharmacogenomics Reporter - Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients
July 25, 2012 / Pharmacogenomics Reporter - Adding Alzheimer's Risk Option, 23andMe Revives Questions on Utility of DTC Genomics
April 20, 2011 / Pharmacogenomics Reporter - Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter